Results of the first bortezomib-based induction therapy in the treatment of multiple myeloma

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.10, 2011-07, pp. : 1661-1663

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib–Dexamethasone or Vincristine–Doxorubicin–Dexamethasone as Induction Therapy Followed by Thalidomide as Maintenance Therapy in Untreated Multiple Myeloma Patients

By Chen RA Tu Y Cao Y Liu L Liang Y

The Journal of International Medical Research, Vol. 39, Iss. 5, 2011-09 ,pp. : 1975-1984

Field House Publishing

Access to resources Recommend Favorite

Bortezomib beats standard therapy in relapsed multiple myeloma

Inpharma, Vol. 1, Iss. 1444, 2004-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Bortezomib in multiple myeloma

By Terpos Evangelos Roussou Maria Dimopoulos Meletios-Athanassios

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 5, 2008-05 ,pp. : 639-654

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib for multiple myeloma

By Popat Rakesh Joel Simon Oakervee Heather Cavenagh Jamie

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 10, 2006-07 ,pp. : 1337-1346

Informa Healthcare

Access to resources Recommend Favorite

Bisphosphonate Therapy in the Treatment of Multiple Myeloma

Current Pharmaceutical Design, Vol. 16, Iss. 27, 2010-01 ,pp. : 3028-3036

Bentham Science Publishers

Access to resources Recommend Favorite